Product Description
Yuhan Corporation is developing YH35995 as an oral treatment to reduce the production of glucosylceramide (GL1), which accumulates in the bodies of patients with Gaucher disease. (Sourced from: https://kormedi.com/1701733/yuhan-gets-phase-1-trial-nod-for-gaucher-disease-treatment/#google_vignette)
Mechanisms of Action: GCS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yuhan
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|